Diacerein Retards Cell Growth of Chondrosarcoma Cells at the G2/M Cell Cycle Checkpoint Via Cyclin B1/CDK1 and CDK2 Downregulation

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2015 Nov 12

PMID 26555773

Citations 17

Authors

Birgit Lohberger

Andreas Leithner

Nicole Stuendl

Heike Kaltenegger

Werner Kullich

Bibiane Steinecker-Frohnwieser

Affiliations

Soon will be listed here.

Abstract

Background: Chondrosarcoma is characterized for its lack of response to conventional cytotoxic chemotherapy, propensity for developing lung metastases, and low rates of survival. Research within the field of development and expansion of new treatment options for unresectable or metastatic diseases is of particular priority. Diacerein, a symptomatic slow acting drug in osteoarthritis (SYSADOA), implicates a therapeutic benefit for the treatment of chondrosarcoma by an antitumor activity.

Methods: After treatment with diacerein the growth behaviour of the cells was analyzed with the xCELLigence system and MTS assay. Cell cycle was examined using flow cytometric analysis, RT-PCR, and western blot analysis of specific checkpoint regulators. The status for phosophorylation of mitogen-activated protein kinases (MAPKs) was analyzed with a proteome profiler assay. In addition, the possible impact of diacerein on apoptosis was investigated using cleaved caspase 3 and Annexin V/PI flow cytometric analysis.

Results: Diacerein decreased the cell viability and the cell proliferation in two different chondrosarcoma cell lines in a dose dependent manner. Flow cytometric analysis showed a classical G2/M arrest. mRNA and protein analysis revealed that diacerein induced a down-regulation of the cyclin B1-CDK1 complex and a reduction in CDK2 expression. Furthermore, diacerein treatment increased the phosphorylation of p38α and p38β MAPKs, and Akt1, Akt2, and Akt 3 in SW-1353, whereas in Cal-78 the opposite effect has been demonstrated. These observations accordingly to our cell cycle flow cytometric analysis and protein expression data may explain the G2/M phase arrest. In addition, no apoptotic induction after diacerein treatment, neither in the Cal-78 nor in the SW-1353 cell line was observed.

Conclusions: Our results demonstrate for the first time that the SYSADOA diacerein decreased the viability of human chondrosarcoma cells and induces G2/M cell cycle arrest by CDK1/cyclin B1 down-regulation.

Citing Articles

The Dose Rate of Corpuscular Ionizing Radiation Strongly Influences the Severity of DNA Damage, Cell Cycle Progression and Cellular Senescence in Human Epidermoid Carcinoma Cells.

Soroko S, Skamnitskiy D, Gorshkova E, Kutova O, Seriev I, Maslennikova A Curr Issues Mol Biol. 2024; 46(12):13860-13880.

PMID: 39727956 PMC: 11726848. DOI: 10.3390/cimb46120828.

Research Progress of Plant-Derived Natural Products against Drug-Resistant Cancer.

Liu W, Wang Y, Xia L, Li J Nutrients. 2024; 16(6).

PMID: 38542707 PMC: 10975298. DOI: 10.3390/nu16060797.

CCNB1 is involved in bladder cancer pathogenesis and silencing CCNB1 decelerates tumor growth and improves prognosis of bladder cancer.

Wang X, Wu H, Yang Y, Ma M, Zhang Y, Huang H Exp Ther Med. 2023; 26(2):382.

PMID: 37456156 PMC: 10347295. DOI: 10.3892/etm.2023.12081.

ATG10 overexpression is related to the dismal prognosis and promotes the growth and migration of hepatocellular carcinoma cells via cyclin B1/CDK1 and CDK2.

Li F, Li K, Li D, Zhang W, Yang K, Ke D Am J Cancer Res. 2023; 13(4):1188-1208.

PMID: 37168332 PMC: 10164811.

Plant-derived natural products and combination therapy in liver cancer.

Wang Y, Li J, Xia L Front Oncol. 2023; 13:1116532.

PMID: 36865794 PMC: 9971944. DOI: 10.3389/fonc.2023.1116532.

References

Cho H, Oh Y, Han S, Chung H, Kim C, Lee N . Cdk1 protein-mediated phosphorylation of receptor-associated protein 80 (RAP80) serine 677 modulates DNA damage-induced G2/M checkpoint and cell survival. J Biol Chem. 2012; 288(6):3768-76. PMC: 3567631. DOI: 10.1074/jbc.M112.401299. View

Damron T, Ward W, Stewart A . Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: National Cancer Data Base Report. Clin Orthop Relat Res. 2007; 459:40-7. DOI: 10.1097/BLO.0b013e318059b8c9. View

Soderstrom M, Ekfors T, Bohling T, Teppo L, Vuorio E, Aro H . No improvement in the overall survival of 194 patients with chondrosarcoma in Finland in 1971-1990. Acta Orthop Scand. 2003; 74(3):344-50. DOI: 10.1080/00016470310014292. View

Xu N, Lao Y, Zhang Y, Gillespie D . Akt: a double-edged sword in cell proliferation and genome stability. J Oncol. 2012; 2012:951724. PMC: 3317191. DOI: 10.1155/2012/951724. View

Zhang W, Liu H . MAPK signal pathways in the regulation of cell proliferation in mammalian cells. Cell Res. 2002; 12(1):9-18. DOI: 10.1038/sj.cr.7290105. View

Nishida K, Furumatsu T, Takada I, Kawai A, Yoshida A, Kunisada T . Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-gamma. Br J Cancer. 2002; 86(8):1303-9. PMC: 2375347. DOI: 10.1038/sj.bjc.6600241. View

Martel-Pelletier J, Mineau F, Jolicoeur F, Cloutier J, Pelletier J . In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998; 25(4):753-62. View

Steinecker-Frohnwieser B, Weigl L, Kullich W, Lohberger B . The disease modifying osteoarthritis drug diacerein is able to antagonize pro inflammatory state of chondrocytes under mild mechanical stimuli. Osteoarthritis Cartilage. 2014; 22(7):1044-52. DOI: 10.1016/j.joca.2014.05.008. View

Gao Y, Moten A, Lin H . Akt: a new activation mechanism. Cell Res. 2014; 24(7):785-6. PMC: 4085759. DOI: 10.1038/cr.2014.57. View

10.

Legendre F, Heuze A, Boukerrouche K, LeClercq S, Boumediene K, Galera P . Rhein, the metabolite of diacerhein, reduces the proliferation of osteoarthritic chondrocytes and synoviocytes without inducing apoptosis. Scand J Rheumatol. 2009; 38(2):104-11. DOI: 10.1080/03009740802421996. View

11.

Kandel E, Skeen J, Majewski N, Di Cristofano A, Pandolfi P, Feliciano C . Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002; 22(22):7831-41. PMC: 134727. DOI: 10.1128/MCB.22.22.7831-7841.2002. View

12.

Montenegro M, Sanchez-Del-Campo L, Fernandez-Perez M, Saez-Ayala M, Cabezas-Herrera J, Rodriguez-Lopez J . Targeting the epigenetic machinery of cancer cells. Oncogene. 2014; 34(2):135-43. DOI: 10.1038/onc.2013.605. View

13.

Vermeulen K, Berneman Z, Bockstaele D . Cell cycle and apoptosis. Cell Prolif. 2003; 36(3):165-75. PMC: 6496173. DOI: 10.1046/j.1365-2184.2003.00267.x. View

14.

Bjornsson J, Mcleod R, Unni K, Ilstrup D, Pritchard D . Primary chondrosarcoma of long bones and limb girdles. Cancer. 1998; 83(10):2105-19. View

15.

DAdamo D . Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol. 2011; 38 Suppl 3:S19-29. DOI: 10.1053/j.seminoncol.2011.09.004. View

16.

Vermeulen K, Bockstaele D, Berneman Z . The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif. 2003; 36(3):131-49. PMC: 6496723. DOI: 10.1046/j.1365-2184.2003.00266.x. View

17.

Pelletier J, Fernandes J, Jovanovic D, Reboul P, Martel-Pelletier J . Chondrocyte death in experimental osteoarthritis is mediated by MEK 1/2 and p38 pathways: role of cyclooxygenase-2 and inducible nitric oxide synthase. J Rheumatol. 2001; 28(11):2509-19. View

18.

Giuffrida A, Burgueno J, Koniaris L, Gutierrez J, Duncan R, Scully S . Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. J Bone Joint Surg Am. 2009; 91(5):1063-72. DOI: 10.2106/JBJS.H.00416. View

19.

Shtivelman E, Sussman J, Stokoe D . A role for PI 3-kinase and PKB activity in the G2/M phase of the cell cycle. Curr Biol. 2002; 12(11):919-24. DOI: 10.1016/s0960-9822(02)00843-6. View

20.

Pawlik T, Keyomarsi K . Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004; 59(4):928-42. DOI: 10.1016/j.ijrobp.2004.03.005. View